Display options
Cite
Lin R, Rahtu-Korpela L, Magga J, et al. miR-1468-3p Promotes Aging-Related Cardiac Fibrosis. Mol Ther Nucleic Acids. 2020;20:589-605doi: 10.1016/j.omtn.2020.04.001.
Lin, R., Rahtu-Korpela, L., Magga, J., Ulvila, J., Swan, J., Kemppi, A., Pakanen, L., Porvari, K., Huikuri, H., Junttila, J., & Kerkelä, R. (2020). miR-1468-3p Promotes Aging-Related Cardiac Fibrosis. Molecular therapy. Nucleic acids, 20589-605. https://doi.org/10.1016/j.omtn.2020.04.001
Lin, Ruizhu, et al. "miR-1468-3p Promotes Aging-Related Cardiac Fibrosis." Molecular therapy. Nucleic acids vol. 20 (2020): 589-605. doi: https://doi.org/10.1016/j.omtn.2020.04.001
Lin R, Rahtu-Korpela L, Magga J, Ulvila J, Swan J, Kemppi A, Pakanen L, Porvari K, Huikuri H, Junttila J, Kerkelä R. miR-1468-3p Promotes Aging-Related Cardiac Fibrosis. Mol Ther Nucleic Acids. 2020 Jun 05;20:589-605. doi: 10.1016/j.omtn.2020.04.001. Epub 2020 Apr 08. PMID: 32348937; PMCID: PMC7191129.
Copy Download .nbib Format: NLM
Share it on

Mol Ther Nucleic Acids. 2020 Jun 05;20:589-605. doi: 10.1016/j.omtn.2020.04.001. Epub 2020 Apr 08.

miR-1468-3p Promotes Aging-Related Cardiac Fibrosis.

Molecular therapy. Nucleic acids

Ruizhu Lin, Lea Rahtu-Korpela, Johanna Magga, Johanna Ulvila, Julia Swan, Anna Kemppi, Lasse Pakanen, Katja Porvari, Heikki Huikuri, Juhani Junttila, Risto Kerkelä

Affiliations

  1. Research Unit of Biomedicine, Department of Pharmacology and Toxicology, University of Oulu, Aapistie 5, 90220 Oulu, Finland.
  2. Research Unit of Biomedicine, Department of Pharmacology and Toxicology, University of Oulu, Aapistie 5, 90220 Oulu, Finland; Biocenter Oulu, University of Oulu, Aapistie 5, 90220 Oulu, Finland.
  3. Department of Forensic Medicine, Research Unit of Internal Medicine, Medical Research Center Oulu, University of Oulu, Aapistie 5, 90220 Oulu, Finland; Forensic Medicine Unit, National Institute for Health and Welfare, Aapistie 5, 90220 Oulu, Finland.
  4. Department of Forensic Medicine, Research Unit of Internal Medicine, Medical Research Center Oulu, University of Oulu, Aapistie 5, 90220 Oulu, Finland.
  5. Division of Cardiology, Research Unit of Internal Medicine, University of Oulu and Oulu University Hospital, Kajaanintie 50, 90220 Oulu, Finland; Medical Research Centre Oulu, Oulu University Hospital and University of Oulu, Aapistie 5, 90220 Oulu, Finland.
  6. Biocenter Oulu, University of Oulu, Aapistie 5, 90220 Oulu, Finland; Division of Cardiology, Research Unit of Internal Medicine, University of Oulu and Oulu University Hospital, Kajaanintie 50, 90220 Oulu, Finland; Medical Research Centre Oulu, Oulu University Hospital and University of Oulu, Aapistie 5, 90220 Oulu, Finland.
  7. Research Unit of Biomedicine, Department of Pharmacology and Toxicology, University of Oulu, Aapistie 5, 90220 Oulu, Finland; Biocenter Oulu, University of Oulu, Aapistie 5, 90220 Oulu, Finland; Medical Research Centre Oulu, Oulu University Hospital and University of Oulu, Aapistie 5, 90220 Oulu, Finland. Electronic address: [email protected].

PMID: 32348937 PMCID: PMC7191129 DOI: 10.1016/j.omtn.2020.04.001

Abstract

Non-coding microRNAs (miRNAs) are powerful regulators of gene expression and critically involved in cardiovascular pathophysiology. The aim of the current study was to identify miRNAs regulating cardiac fibrosis. Cardiac samples of age-matched control subjects and sudden cardiac death (SCD) victims with primary myocardial fibrosis (PMF) were subjected to miRNA profiling. Old SCD victims with PMF and healthy aged human hearts showed increased expression of miR-1468-3p. In vitro studies in human cardiac fibroblasts showed that augmenting miR-1468-3p levels induces collagen deposition and cell metabolic activity and enhances collagen 1, connective tissue growth factor, and periostin expression. In addition, miR-1468-3p promotes cellular senescence with increased senescence-associated β-galactosidase activity and increased expression of p53 and p16. AntimiR-1468-3p antagonized transforming growth factor β1 (TGF-β1)-induced collagen deposition and metabolic activity. Mechanistically, mimic-1468-3p enhanced p38 phosphorylation, while antimiR-1468-3p decreased TGF-β1-induced p38 activation and abolished p38-induced collagen deposition. RNA sequencing analysis, a computational prediction model, and qPCR analysis identified dual-specificity phosphatases (DUSPs) as miR-1468-3p target genes, and regulation of DUSP1 by miR-1468-3p was confirmed with a dual-luciferase reporter assay. In conclusion, miR-1468-3p promotes cardiac fibrosis by enhancing TGF-β1-p38 signaling. Targeting miR-1468-3p in the older population may be of therapeutic interest to reduce cardiac fibrosis.

Copyright © 2020 The Author(s). Published by Elsevier Inc. All rights reserved.

Keywords: aging; cardiac fibrosis; dual-specificity phosphatases; extracellular matrix; miR-1468-3p; microRNA; p38; senescence

References

  1. Nat Rev Genet. 2011 Nov 18;12(12):846-60 - PubMed
  2. Mol Ther Nucleic Acids. 2017 Mar 17;6:106-115 - PubMed
  3. PLoS One. 2013 Sep 11;8(9):e74535 - PubMed
  4. Genome Res. 2006 Oct;16(10):1289-98 - PubMed
  5. Circulation. 2005 May 17;111(19):2430-7 - PubMed
  6. Mol Cell Endocrinol. 2011 May 16;338(1-2):18-27 - PubMed
  7. Nat Rev Cardiol. 2018 Sep;15(9):566-577 - PubMed
  8. J Clin Invest. 2017 Oct 2;127(10):3770-3783 - PubMed
  9. Circ Res. 2013 Jan 4;112(1):48-56 - PubMed
  10. Nat Commun. 2018 Jul 2;9(1):2560 - PubMed
  11. Int J Cancer. 2012 Apr 15;130(8):1715-25 - PubMed
  12. J Biol Chem. 2008 Nov 7;283(45):31246-55 - PubMed
  13. Dev Cell. 2009 Jul;17(1):142-9 - PubMed
  14. J Mol Cell Cardiol. 2016 Dec;101:44-49 - PubMed
  15. Trends Cell Biol. 2018 Jun;28(6):436-453 - PubMed
  16. Circulation. 2018 Jun 19;137(25):2716-2726 - PubMed
  17. Heart Rhythm. 2011 Oct;8(10):1570-5 - PubMed
  18. N Engl J Med. 2015 Mar 19;372(12):1138-49 - PubMed
  19. Circulation. 2012 Sep 4;126(10):1206-16 - PubMed
  20. Nat Rev Cardiol. 2018 Sep;15(9):523-542 - PubMed
  21. J Biol Chem. 2002 Aug 30;277(35):31818-25 - PubMed
  22. Circulation. 2018 Feb 13;137(7):707-724 - PubMed
  23. Nat Rev Mol Cell Biol. 2012 Oct;13(10):616-30 - PubMed
  24. Nat Med. 2015 Dec;21(12):1424-35 - PubMed
  25. Cardiovasc Res. 2004 Dec 1;64(3):526-35 - PubMed
  26. Nat Rev Clin Oncol. 2018 Sep;15(9):541-563 - PubMed
  27. Circulation. 2019 Feb 19;139(8):1012-1021 - PubMed
  28. Circulation. 2016 Jan 19;133(3):291-301 - PubMed
  29. Nat Rev Mol Cell Biol. 2007 Sep;8(9):729-40 - PubMed
  30. Nat Commun. 2018 Mar 9;9(1):1020 - PubMed
  31. Nat Rev Cardiol. 2013 Jan;10(1):15-26 - PubMed
  32. Circulation. 2017 Aug 8;136(6):549-561 - PubMed
  33. Cold Spring Harb Perspect Biol. 2011 Nov 01;3(11):a005017 - PubMed
  34. Trends Mol Med. 2017 Jan;23(1):6-17 - PubMed
  35. Nat Rev Mol Cell Biol. 2019 Jan;20(1):21-37 - PubMed
  36. Nat Med. 2007 Aug;13(8):952-61 - PubMed
  37. Nat Commun. 2017 Feb 23;8:14532 - PubMed
  38. J Am Coll Cardiol. 2016 May 3;67(17):2018-28 - PubMed
  39. Nat Rev Cancer. 2009 Aug;9(8):537-49 - PubMed
  40. J Biol Chem. 2001 Aug 24;276(34):32382-91 - PubMed
  41. Nat Rev Immunol. 2007 Mar;7(3):202-12 - PubMed
  42. Circulation. 2018 Sep 18;138(12):1236-1252 - PubMed
  43. Proc Natl Acad Sci U S A. 2007 Aug 28;104(35):14074-9 - PubMed
  44. Gene. 2016 Jan 10;575(2 Pt 2):369-376 - PubMed
  45. Proc Natl Acad Sci U S A. 2008 Sep 2;105(35):13027-32 - PubMed
  46. Oncogene. 2012 Apr 12;31(15):1949-62 - PubMed
  47. Circ Res. 2016 Feb 5;118(3):400-9 - PubMed
  48. Hypertension. 2015 Oct;66(4):776-85 - PubMed
  49. Eur Heart J. 2010 Nov;31(22):2765-73 - PubMed
  50. Theranostics. 2018 Apr 3;8(9):2565-2582 - PubMed
  51. Nature. 2016 Feb 11;530(7589):184-9 - PubMed
  52. J Clin Invest. 2017 May 1;127(5):1600-1612 - PubMed
  53. Cell Rep. 2017 Mar 7;18(10):2480-2493 - PubMed
  54. Nat Rev Mol Cell Biol. 2014 Jul;15(7):482-96 - PubMed

Publication Types